Private, no accountPrivacy details: browsing privately, no account needed
You're browsing privately, no account needed. Your region stays in this session and your precise location is never stored.What we store
H.R. 6863 · 116th CongressIn committee

COVID–19 Accountability Act

Latest action. Referred to the Committee on Foreign Affairs, and in addition to the Committees on the Judiciary, Financial Services, Ways and Means, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdictionA court's legal authority to hear a case: over the subject matter, the parties, and the territory.Read the full definition (opens a new tab) of the committee concerned. · May 14, 2020

Live record from Congress.gov, updated as the official record changes.
What this bill would do
Official summary · Congressional Research Service

COVID-19 Accountability Act

This bill authorizes sanctions in relation to the Chinese government's response to the COVID-19 (i.e., coronavirus disease 2019) outbreak. It also increases the research tax credit and imposes requirements related to the acquisition of items for the Strategic National Stockpile.

The President shall periodically certify to Congress that the Chinese government (1) is cooperating with efforts related to the COVID-19 outbreak, (2) has prohibited wet markets, and (3) has released and dropped all charges for anyone involved in protests in Hong Kong related to COVID-19. If the President cannot make such a certification, the President may (1) impose sanctions on Chinese government officials, entities owned or controlled by the Chinese government, and individuals affiliated with such entities; or (2) prohibit Chinese nationals from obtaining student visas (i.e., F and M visas) or exchange visitor visas (i.e., J visas).

With respect to the research tax credit, the bill increases the alternative simplified credit from 14% to 20% of qualified research expenses above a certain threshold.

The Department of Health and Human Services generally may not purchase personal protective equipment, critical medical supplies, or certain fabric products not produced in the United States for the Strategic National Stockpile. However, this restriction shall not apply if (1) there is not a sufficient amount of U.S.-produced items available at U.S. market prices when needed, or (2) the purchase is worth less than $150,000.

Written by analysts at the Congressional Research Service and published on Congress.gov, not by Civibrief. Summarized at the "Introduced in House" stage on May 14, 2020. It describes the bill, it is not the legal text.

Status
Introduced
May 14, 2020
In committee
May 14, 2020
Passed a chamber
Cleared Congress
Enacted
Where this sits in the process
Common questions
Composed from the official record
Where is it in the process, and what happens next?

4 steps remain before this bill could become law.

The record's latest action, on May 14, 2020: Referred to the Committee on Foreign Affairs, and in addition to the Committees on the Judiciary, Financial Services, Ways and Means, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  1. Clearing the committees it was referred to, and being scheduled for a floor vote
  2. Passage by the House
  3. Passage by the Senate
  4. The President's signature. If the President vetoes it, two-thirds of both chambers must vote to override.
How likely is it to become law?

Civibrief does not forecast outcomes and this page has no opinion about this one. What the record supports is a base rate, which is a fact about the whole pile, not a prediction about this measure.

In the 116th Congress (2019-20), 344 of the 14,345 bills and joint resolutions introduced became law, about 2.4 percent. That count covers every measure at every stage, including the many that never left committee.

This one is not there yet: 4 steps are still outstanding, listed above.

Has anyone actually voted on it?

No. No roll call in this Congress cites this measure. That is the ordinary outcome: most measures never reach a recorded floor vote, and a committee ends most of them simply by not acting.

A vote is not the only thing that happens to a measure. Hearings, markups, and referrals are all recorded actions, and none of them is a vote of the full chamber.

Who is behind it?

Doug Collins (R-GA) introduced it on May 14, 2020, and 32 members have since signed on as cosponsors.

They are 32 Republicans.

Cosponsoring is a formal signature on the text. It is not a commitment to vote for the measure, it does not bind anyone's party, and a long list of cosponsors is a measure of attention rather than of prospects.

How long has it been in play?

It was introduced on May 14, 2020, 2310 days ago. The most recent recorded action was 2310 days ago, on May 14, 2020.

Measures do not carry over. Anything the 116th Congress has not finished by January 3, 2021 dies when the term ends, and has to be introduced again from the start in the next Congress.

Every answer above is assembled from this measure's own record on Congress.gov and from published counts of what Congress has passed before. Civibrief does not predict outcomes and takes no position on any measure.

Vote history

  1. House
    In committee, no floor vote yet
  2. Senate
    Awaits House passage
  3. President
    Awaits both chambers
No recorded votes yet
No roll call in this Congress cites this bill. Most bills die in committee without ever reaching a recorded floor vote.